Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today ...

On October 30, Matthew Fienup (Executive Director, Center for Economic Research and Forecasting) and Gerhard Apfelthaler, ...

Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue - - Reports positive feedback from the FDA ...

Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license ...

The global calcium supplement market is projected to grow from USD 6.19 billion in 2025 to USD 9.22 billion by 2035, ...

A powerful recruiting ecosystem to help you find career opportunities and engage with recruiters and companies.

Before the GLP-1 boom of recent years, the pharmaceutical industry had begun to shift away from blockbuster drugs towards specialized, personalized therapies, such as Cell & Gene Therapies (CGT’s) and ...

2030–2035: The market increases from USD 257.8 million to USD 327.2 million, delivering more than half (56%) of total decade ...

After announcing earlier this week the appointment of Andreas Wallnöfer, PhD, MBA, to its Board of Directors, Optigo ...

Dr. Andreas Wallnöfer joins Optigo Biotherapeutics' Board, bringing expertise from Jeito Capital, BioMedPartners, and Roche.

Direct-to-consumer drug sales aim to simplify pricing and increase transparency by allowing patients to buy directly from ...